Introduction Alzheimer's disease and related dementias (ADRD) disproportionately impact
racial and ethnic minority and socioeconomically disadvantaged adults. Yet, these …

Clinical Alzheimer's disease (AD) trials currently face a critical shortfall of thousands of
eligible participants, which inflates the duration and cost of the clinical study as well as …

Purpose of the study: Investigating health disparities requires studies designed to recruit and
retain racially and socioeconomically diverse cohorts. It is critical to address the barriers that …

To generalize findings on the mechanisms and prognosis in Alzheimer's disease and
related dementias (ADRD), it is critical for ADRD research to be representative of the …

The 2012 National Plan to Address Alzheimer's Disease set an ambitious goal: to both
prevent and effectively treat Alzheimer's disease by 2025. To reach this goal, tens of …

Background Two main genetic risks for sporadic Alzheimer's disease (AD) are a family
history and ɛ4 allele of apolipoprotein E. The brain and retina are part of the central nervous …

Patient registries are valuable tools helping to address significant challenges in research,
care, and policy. Registries, well embedded in many fields of medicine and public health …

Introduction Subjective cognitive decline (SCD) may indicate unhealthy cognitive changes,
but no standardized SCD measurement exists. This pilot study aimed to identify reliable …

Introduction Alzheimer's disease (AD) incidence is disproportionately high in African
Americans, yet, recruitment of this community to AD clinical trials is challenging. Methods We …

Background The mismatch between the limited availability versus the high demand of
participants who are in the pre-dementia phase of Alzheimer's disease (AD) is a bottleneck …